Analyzing Praxsyn (OTCMKTS:PXYN) and FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) and Praxsyn (OTCMKTS:PXYN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for FibroGen and Praxsyn, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroGen	1	1	1	0	2.00
Praxsyn	0	0	0	0	0.00

FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 400.00%. Given FibroGen’s stronger consensus rating and higher possible upside, equities analysts clearly believe FibroGen is more favorable than Praxsyn.

Profitability

This table compares FibroGen and Praxsyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FibroGen	2,598.55%	N/A	-26.27%
Praxsyn	N/A	N/A	N/A

Insider & Institutional Ownership

72.7% of FibroGen shares are held by institutional investors. 3.1% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares FibroGen and Praxsyn”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroGen	$29.62 million	1.18	-$47.58 million	$53.48	0.16
Praxsyn	N/A	N/A	N/A	N/A	N/A

Praxsyn has lower revenue, but higher earnings than FibroGen.

Volatility and Risk

FibroGen has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Praxsyn has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.

Summary

FibroGen beats Praxsyn on 7 of the 9 factors compared between the two stocks.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About Praxsyn

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers’ compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.